Metabolic bone disease in inflammatory bowel disease

Schulte CM, Dignass AU, Goebell H, et al.: Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000, 119:909–920. Bernstein CN, Seeger LL, Sayre JW, et al.: Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995, 10:250–256. Harrison JE, Hitchman AJW, Finlay JM, McNeil KG: Calcium kinetic studies in patients with malabsorption syndromes. Gastroenterology 1969, 56:751–757. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH: Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology 1982, 83:1252–1258. Schoan EJ, Muller MCA, Vermeer C, et al.: Low serum and bone vitamin K status in patients with longstanding Crohn’s disease: another pathogenetic factor of osteoporosis in Crohn’s disease? Gut 2001, 48:473–477. Robinson RJ, Iqbal SJ, Abrams K, et al.: Increased bone resorption in patients with Crohn’s disease. Aliment Pharmacol Ther 1998, 12:699–705. Bjarnason I, MacPherson A, Mackintosh C, et al.: Reduced bone mineral density in patients with inflammatory bowel disease. Gut 1997, 40:228–239. Croucher PI, Vedi S, Motley RJ, et al.: Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporosis Int 1993, 3:236–241. Sambrook PN, Kelly PJ, Keogh AM, et al.: Bone loss after heart transplantation: a prospective study. J Heart Lung Transpl 1994, 13:116–121. Stempfle HU, Wehr U, Meiser B, et al.: Effect of FK506 (tacrolimus) on trabecular bone loss shortly after cardiac transplantation [abstract]. J Bone Miner Res 1996, 11:S127. Gnudi S, Butturini L, Ripamonti C, et al.: The effects of methotrexate (MTX) on bone: a densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol 1988, 14:227–231. Lindsay R, Haart DM, Forrest C, Baird C: Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980, 2:1151–1153. Robinson RJ, Iqbal SJ, Al-Azzawi F, et al.: Sex hormone status and bone metabolism in men with Crohn’s disease. Aliment Pharmacol Ther 1998, 12:21–25. Silvennoinen A, Lehtola JK, Niemela SE: Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996, 31:367–371. Robinson RJ, Krzywicki T, Almond L, et al.: Effect of low-impact exercise program on bone mineral density in Crohn’s disease: a randomized controlled trial. Gastroenterology 1998, 115:36–41. Wahner HW: Single and dual photon absorptiometry in osteoporosis and osteomalacia. Semin Nucl Med 1987, 27:305–315. Papaioannou A, Ferko NC, Adachi JD: All patients with inflammatory bowel disease should have bone density assessment: Pro. Inflamm Bowel Dis 2001, 7:158–162. Ott SM, Kilcoyne RF, Chesnut CH III: Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women. J Bone Miner Res 1987, 2:201–210. Wahner HW: Single and dual photon absorptiometry in osteoporosis and osteomalacia. Semin Nucl Med 1987, 27:305–315. Berstein CN, Blanchard JF, Leslie W, et al.: The incidence of fracture among patients with inflammatory bowel disease. Ann Intern Med 2000, 133:795–799. This population-based report describes the increased incidence of spine, hip, wrist/forearm, and rib fractures in patients with either Crohn’s disease or ulcerative colitis. Buchman AL: Bones and Crohn’s: problems and solutions. Inflamm Bowel Dis 1999, 5:212–227. This is a comprehensive review of the pathophysiology and treatment of bone and joint disease in people with IBD. Reginster JY, Deroisy R, Rovati LC, et al.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001, 357:251–256. Cino M, Greenberg GR: Bone mineral density in Crohn’s disease patients receiving long-term budesonide [abstract]. Gastroenterology 1998, 114:A952. D’Haens G, Verstraete A, Cheyns K, et al.: Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther 1998, 12:419–424. Ringe JD, Welzel D: Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987, 33:35–39. Chestnut CH, Silverman S, Andriano K, et al.: A randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000, 109:267–276. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. In this study, BMD increased and the incidence of both vertebral and nonvertebral fractures decreased in association with daily PTH injections. Lane NE, Roe B, Genant HK, Arnaud CD: Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomized, controlled trial [abstract]. Arthritis Rheum 1997, 40:S324. Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000, 119:639–646. Alendronate therapy was associated with an increase in hip BMD, although the study was to small and too short to evaluate the effect on fracture risk. Crandall C: Risedronate: a clinical review. Arch Intern Med 2001, 161:353–360. A comprehensive review of the randomized, placebocontrolled trials of risedronate. Bartram SA, Francis RM, Thompson NP: A randomized trial of intravenous pamidronate and calcium and vitamin D in the treatment of osteoporosis associated with Crohn’s disease [abstract]. Gastroenterology 2001, A627. Illich JZ, Kerstetter JE: Nutrition in bone health revisited: a story beyond calcium. J Am Coll Nutr 2000, 19:715–737. A comprehensive review of dietary factors important in the maintenance of normal bone.